Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY23 Guidance
November 8, 2023 7:10 AM ESTTeva Pharma (NYSE: TEVA) reported Q3 EPS of $0.60, in-line with the analyst estimate of $0.60. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.72 billion.
GUIDANCE:
Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus of... More
